Video
What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)
Author(s):
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Ophthalmology Times'® group editorial director, during the virtual 2020 American Society of Glaucoma Specialists (ASRS) annual meeting.
Related Videos
Part 3: Biggest innovations in ophthalmology in 50 years
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
Part 2: Biggest innovations in ophthalmology in 50 years
Anat Loewenstein comments on the recent FDA approval of revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2 treatment
Envision Summit 2025: Eradicating TRD
Envision Summit 2025: Deep learning models of neovascular AMD
Envision Summit 2025: Beyond the status quo in gene therapy
Envision Summit 2025: Understanding hyperglycemia in diabetic retinopathy
Envision Summit 2025: Difficulties in diagnosing inherited retinal degenerations
Envision Summit 2025: Managing add-ons in a busy retina clinic
Related Content
